Gcpeg 6mg Injection

About

Gcpeg 6mg Injection contains pegfilgrastim, a pegylated form of recombinant human granulocyte colony-stimulating factor (G-CSF). It works by stimulating the production, maturation, and release of neutrophils from the bone marrow. Neutrophils are a type of white blood cell crucial for fighting infections, forming a key part of the body's innate immune response. By increasing neutrophil counts, pegfilgrastim helps to reduce the incidence and duration of febrile neutropenia, a common and serious complication of myelosuppressive chemotherapy. The pegylation process extends the half-life of filgrastim, allowing for a single dose per chemotherapy cycle, which significantly improves patient convenience and adherence compared to daily G-CSF injections. This prophylactic measure is vital in maintaining chemotherapy dose intensity and reducing the risk of life-threatening infections, thereby supporting overall treatment outcomes and enhancing patient safety during cancer therapy.

Uses

• Prevention of febrile neutropenia in cancer patients.
• Used after myelosuppressive chemotherapy.
• Reduces the incidence of infection associated with neutropenia.
• Supports chemotherapy dose intensity.

Directions For Use

Administer as a single subcutaneous injection approximately 24 hours after cytotoxic chemotherapy. Do not administer within 14 days before or 24 hours after administration of cytotoxic chemotherapy.

Benefits

• Reduces risk of serious infections.
• Supports immune system during chemotherapy.
• Single dose per chemotherapy cycle.
• Convenient for patients and caregivers.
• Allows for consistent chemotherapy dosing.
• Improves patient quality of life by preventing complications.

Side Effects

• Bone pain
• Muscle pain
• Headache
• Nausea
• Fatigue
• Injection site reactions
• Splenomegaly (rare)
• Allergic reactions (rare)
• Leukocytosis
• Thrombocytopenia
• Alopecia
• Diarrhea

Safety Measures

• Alcohol - No specific contraindication with alcohol, but general health recommendations apply, especially during cancer treatment.
• Pregnancy - Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult a physician.
• Breastfeeding - It is unknown if pegfilgrastim is excreted in human milk. Caution should be exercised when administered to a breastfeeding woman.
• Liver - No specific dose adjustment is typically required for liver impairment.
• Kidney - No specific dose adjustment is typically required for renal impairment.
• Lung - Rare cases of acute respiratory distress syndrome (ARDS) have been reported; monitor for pulmonary symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.